Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Obesity Surgery
Published in: Obesity Surgery 4/2020

01-04-2020 | Bariatric Surgery | Original Contributions

Impact of Gastric Bypass on Erosive Esophagitis and Barret’s Esophagus

Authors: Franco Signorini, German Viscido, María Cecilia Anastasía Bocco, Lucio Obeide, Federico Moser

Published in: Obesity Surgery | Issue 4/2020

Login to get access

Abstract

Background

The association between gastroesophageal reflux disease (GERD) and obesity is clearly defined. The incidence of erosive esophagitis (EE) and Barrett’s esophagus (BE) are as high as 26 and 6%, respectively. Gastric bypass (GBP) is considered the gold standard for obese patients with GERD. Evidence about the impact of GBP on EE and BE is not yet clear but more inspiring every day.

Methods

Obese patients operated by GBP with EE or BE were included for this study. Demographics, BMI, %EWL, and the evolution of EE and BE with pre and postoperative upper endoscopy were analyzed.

Results

In this study, 64 patients were included, 55 with EE and 9 with BE. The preoperative BMI was 44.29 km/m2 ± 3.5 and the %EWL was 78.5 ± 5.8 in the first year postoperative. Preoperatively, EE was distributed as follows: A: 54.5% (30), B: 34.5% (19), C: 9% (5), D: 2% (1). BE findings were the following: short segment (SSBE): 45% (4) and long segment (LSBE): 55% (5). Postoperatively, 80% of the patients with EE resolved their condition, 11% improved, 7% had no changes, and 2% worsened. From the patients with SSBE, 75% resolved their condition and 40% with LSBE resolved their condition after 24 months and no patient progressed to dysplasia.

Conclusion

Patients with EE had a statistically significant resolution after GBP. BE was improved or even resolved in many patients without acquiring significance but also without progression. Long-term surveillance data is necessary to define the certain evolution of EE and BE after GBP.
Literature
1.
Hong D, Khajanchee YS, Pereira N, et al. Manometric abnormalities and gastroesophageal reflux disease in the morbidly obese. Obes Surg. 2004;14:744–9.PubMed
2.
Nelson LG, Gonzalez R, Haines K, et al. Amelioration of gastroesophageal reflux symptoms following roux-en-Y gastric bypass for clinically significant obesity. Am Surg. 2005;71:950–3.PubMed
3.
El-Serag HB, Ergun GA, Pandolfino J, et al. Obesity increases oesophageal acid exposure. Gut. 2007;56:749–55.PubMed
4.
Friedenberg FK, Xanthopoulos M, Foster GD, et al. The association between gastroesophageal reflux disease and obesity. Am J Gastroenterol. 2008;103:2111–22.PubMed
5.
Corley DA, Kubo A. Body mass index and gastroesophageal reflux disease: a systematic review and meta-analysis. Am J Gastroenterol. 2006;101:2619–28.PubMed
6.
Braghetto I, Korn O, Csendes A, et al. Laparoscopic treatment of obese patients with Gastroesophageal reflux disease and Barrett’s esophagus: a prospective study. Obes Surg. 2012;22:764–72.PubMed
7.
Gorodner V, Buxhoeveden R, Clemente G, et al. Barrett’s esophagus after roux-en-Y gastric bypass: does regression occur? Surg Endosc. 2017;31:1849–54.PubMed
8.
Koo JS, Lee SW, Park SM, et al. Abdominal obesity as a risk factor for the development of erosive esophagitis in subjects with a Normal Esophago-gastric junction. Gut Liver. 2009;3:276–84.PubMedPubMedCentral
9.
El-Serag H, Graham D, Satia J, et al. Obesity is an Independient risk factor for GERD symptoms and erosive esophagitis. Am J Gastroenterol. 2005;100:1243–50.PubMed
10.
Csendes A, Burgos A, Smok G, et al. Endoscopic and histologic findings of the foregut in 426 patients with morbid obesity. Obes Surg. 2007;17:28–34.PubMed
11.
Schigt A, Coblijn U, Lagarde S, et al. Is esophagogastroduodenoscopy before roux-en-Y gastric bypass or sleeve gastrectomy mandatory? Surg Obes Relat Dis. 2014;10:411–8.PubMed
12.
Peromaa-Haavisto P, Victorzon M. Is routine preoperative upper GI endoscopy needed prior to gastric bypass? Obes Surg. 2013;23:736–9.PubMed
13.
Muñoz R, Ibañez L, Salinas J, et al. Importance of routine preoperative upper GI endoscopy: why all patients should be evaluated? Obes Surg. 2009;19:427–31.PubMed
14.
Fisichella PM, Patti MG. Gastroesophageal reflux disease and morbid obesity: is there a relation? World J Surg. 2009;33:2034–8.PubMed
15.
Prachand VN, Alverdy JC. Gastroesophageal reflux disease and severe obesity: fundoplication or bariatric surgery? World J Gastroenterol. 2010;16:3757–61.PubMedPubMedCentral
16.
Morrow E, Bushyhead D, Wassenaar E, et al. The impact of laparoscopic anti-reflux surgery in patients with Barrett’s esophagus. Surg Endosc. 2014;28:3279–84.PubMed
17.
Perez AR, Moncure AC, Rattner DW. Obesity adversely affects the outcome of antireflux operations. Surg Endosc. 2001;15:986–9.PubMed
18.
Morgenthal CB, Lin E, Shane MD, et al. Who will fail laparoscopic Nissen fundoplication? Preoperative prediction of long-term outcomes. Surg Endosc. 2007;21:1978–84.PubMed
19.
Braghetto I, Korn O, Valladares H, et al. Laparoscopic surgical treatment for patients with short- and long segment Barrett’s esophagus: which technique in which patient? Int Surg. 2011;96:95–103.PubMed
20.
Tekin K, Toydemir T, Yerdel MA. Is laparoscopic antireflux surgery safe and effective in obese patients? Surg Endosc. 2012;26:86–95.PubMed
21.
Anvari M, Bamehriz F. Outcome of laparoscopic Nissen fundoplication in patients with body mass index >or=35. Surg Endosc. 2006;20:230–4.PubMed
22.
Winslow ER, Frisella MM, Soper NJ, et al. Obesity does not adversely affect the outcome of laparoscopic antireflux surgery (LARS). Surg Endosc. 2003;17:2003–11.PubMed
23.
Chisholm JA, Jamieson GG, Lally CJ, et al. The effect of obesity on the outcome of laparoscopic antireflux surgery. J Gastrointest Surg. 2009;13:1064–70.PubMed
24.
D'Alessio MJ, Arnaoutakis D, Giarelli N, et al. Obesity is not a contraindication to laparoscopic Nissen fundoplication. J Gastrointest Surg. 2005;9:949–54.PubMed
25.
Fraser J, Watson DI, O’Boyle CJ, et al. Obesity and its effect on outcome of laparoscopic Nissen fundoplication. Dis Esophagus. 2001;14:50–3.PubMed
26.
Broeders JA, Draaisma WA, Bredenoord AJ, et al. Long-term outcome of Nissen fundoplication in non-erosive and erosive gastro-oesophageal reflux disease. Br J Surg. 2010;97:845–52.PubMed
27.
Oelschlager BK, Barreca M, Chang L, et al. Clinical and pathologic response of Barrett’s esophagus to laparoscopic antireflux surgery. Ann Surg. 2003;238:458–64.PubMedPubMedCentral
28.
O'Riordan JM, Byrne PJ, Ravi N, et al. Long-term clinical and pathologic response of Barrett’s esophagus after antireflux surgery. Am J Surg. 2004;188:27–33.PubMed
29.
Madalosso CA, Gurski RR, Callegari-Jacques SM, et al. The impact of gastric bypass on gastroesophageal reflux disease in patients with morbid obesity: a prospective study based on the Montreal consensus. Ann Surg. 2010;251:244–8.PubMed
30.
Nelson LG, Gonzalez R, Haines K, et al. Amelioration of gastroesophageal reflux symptoms following Roux-en-Y gastric bypass for clinically significant obesity. Am Surg. 2005;71:950–3.PubMed
31.
Frezza EE, Ikramuddin S, Gourash W, et al. Schauer. Symptomatic improvement in gastroesophageal reflux disease (GERD) following laparoscopic Roux-en-Y gastric bypass. Surg Endosc. 2002;16(7):1027–31.PubMed
32.
Perry Y, Courcoulas AP, Fernando HC, et al. Laparoscopic Roux-en-Y gastric bypass for recalcitrant gastroesophageal reflux disease in morbidly obese patients. JSLS. 2004;8:19–23.PubMedPubMedCentral
33.
Kindel TL, Oleynikov D. The improvement of gastroesophageal reflux disease and Barrett’s after bariatric surgery. Obes Surg. 2016;26:718–20.PubMed
34.
Andrew B, Alley JB, Aguilar CE, et al. Barrett's esophagus before and after Roux-en-Y gastric bypass for severe obesity. Surg Endosc. 2018;32(2):930–6.PubMed
35.
Csendes A, Burgos AM, Smok G, et al. Effect of gastric bypass on Barrett’s esophagus and intestinal metaplasia of the cardia in patients with morbid obesity. J Gastrointest Surg. 2006;10:259–64.PubMed
36.
Houghton SG, Romero Y, Sarr MG. Effect of Roux-en-Y gastric bypass in obese patients with Barrett's esophagus: attempts to eliminate duodenogastric reflux. Surg Obes Relat Dis. 2008;4:1–4.PubMed
37.
Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999;45:172–80.PubMedPubMedCentral
38.
Levine DS, Haggitt RC, Blount PL, et al. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett’s esophagus. Gastroenterology. 1993;105:40–50.PubMed
39.
Barr AC, Frelich MJ, Bosler ME, et al. GERD and acid reduction medication use following gastric bypass and sleeve gastrectomy. Surg Endosc. 2017;31:410–5.PubMed
40.
Stein DJ, El-Serag HB, Kuczynski J, et al. The association of body mass index with Barrett's oesophagus. Aliment Pharmacol Ther. 2005;22:1005–10.PubMed
41.
42.
Merrouche M, Sabaté JM, Jouet P, et al. Gastro-esophagealreflux and esophageal motility disorders in morbidly obese patients before and after bariatric surgery. Obes Surg. 2007;17:894–900.PubMed
43.
Pallati PK, Shaligram A, Shostrom VK, et al. Improvement in gastroesophageal reflux disease symptoms after various bariatric procedures: review of the Bariatric Outcomes Longitudinal Database. Surg Obes Relat Dis. 2014;10:502–7.PubMed
44.
Jackson TD, Hutter MM. Morbidity and effectiveness of laparoscopic sleeve gastrectomy, adjustable gastric band, and gastric bypass for morbid obesity. Adv Surg. 2012;46:255–68.PubMed
45.
Csendes A, Smok G, Burgos AM, et al. Prospective sequential endoscopic and histologic studies of the gastric pouch in 130 morbidly obese patients submitted to Roux-en-Y gastric bypass. Arq Bras Cir Dig. 2012;25:245–9.PubMed
46.
Spechler SJ, Souza RF. Barrett’s esophagus. N Engl J Med. 2014;37:836–45.
47.
Hofstetter WL, Peters JH, DeMeester TR, et al. Long-term outcome of antireflux surgery in patients with Barrett’s esophagus. Ann Surg. 2001;234:532–8.PubMedPubMedCentral
48.
Czeczko LE, Cruz MA, Klostermann FC, et al. Correlation between pre and postoperative upper digestive endoscopy in patients who underwent Roux-en-Y gastrojejunal bypass. Arq Bras Cir Dig. 2016;29:33–7.PubMedPubMedCentral
49.
Thrift AP, Shaheen NJ, Gammon MD, et al. Obesity and risk of esophageal adenocarcinoma and Barrett’s esophagus: a Mendelian randomization study. J Natl Cancer Inst. 2014;106:dju252.PubMedPubMedCentral
Metadata
Title
Impact of Gastric Bypass on Erosive Esophagitis and Barret’s Esophagus
Authors
Franco Signorini
German Viscido
María Cecilia Anastasía Bocco
Lucio Obeide
Federico Moser
Publication date
01-04-2020
Publisher
Springer US
Published in
Obesity Surgery / Issue 4/2020
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-019-04333-1

Other articles of this Issue 4/2020

Obesity Surgery 4/2020 Go to the issue

Original Contributions

The Influence of Persistent Organic Pollutants on Thyroidal, Reproductive and Adrenal Hormones After Bariatric Surgery

Brief Communication

A MOOC About Bariatric Surgery Improves Knowledge and Promotes Patients’ Soft Skills

Original Contributions

One Anastomosis Gastric Bypass–Mini-Gastric Bypass (OAGB-MGB) Versus Roux-en-Y Gastric Bypass (RYGB)—a Mid-Term Cohort Study with 612 Patients

Original Contributions

Bariatric Surgery in Cirrhotic Patients: Is It Safe?

Original Contributions

Variable Thresholds of Vitamin D Plasma Levels to Suppress PTH: the Effect of Weight and Bariatric Surgery

Review

Indications, Operative Techniques, and Outcomes for Revisional Operation Following Mini-Gastric Bypass-One Anastomosis Gastric Bypass: a Systematic Review